文献速递呼吸道感染呼吸危重症与机械通气

57岁男性COVID-19肺炎需VV-ECMO期间白细胞快速升高

A 57-Year-Old Man With COVID-19 Pneumonia Who Required Venovenous Extracorporeal Life Support With a Rapidly Escalating WBC Count.
PubMed 文献 · Chest · 2021-01-01

一名57岁男性因COVID-19肺炎致低氧性呼吸衰竭,接受有创通气及静脉-静脉体外膜氧合(VV-ECMO)支持。在ECMO第13至17天,白细胞计数从17,500升至47,000 cells/μL,同期出现液体难治性休克需多种血管加压药,并开始广谱抗微生物治疗(含抗真菌及抗蠕虫)。

要点

  • COVID-19肺炎VV-ECMO支持者可出现白细胞快速升高,需警惕继发感染或炎症反应。
  • 白细胞升高期间可并发液体难治性休克,需血管加压药支持。
  • 广谱抗微生物治疗需覆盖真菌及寄生虫可能,但需结合临床评估。

核心结论

  • COVID-19肺炎接受VV-ECMO支持的患者在ECMO第13至17天出现白细胞从17,500升至47,000 cells/μL,并伴液体难治性休克。

研究设计与样本

  • 单例病例报告:57岁男性,因COVID-19肺炎低氧性呼吸衰竭插管并接受VV-ECMO后转至作者机构。

主要发现

  • ECMO第13至17天,白细胞计数从17,500 cells/μL升至47,000 cells/μL。
  • 同期出现液体难治性休克,需多种血管加压药,白细胞30,000 cells/μL时接受应激剂量氢化可的松。
  • 患者始终无发热,启动包括抗真菌及抗蠕虫的广谱抗微生物治疗。

关键数值与推荐

  • 静脉肝素抗凝,抗Xa因子目标0.1至0.3 international unit/mL。
  • 白细胞30,000 cells/μL时给予应激剂量氢化可的松。

临床怎么用

  • VV-ECMO支持的COVID-19肺炎患者出现白细胞快速升高时,应评估继发感染及炎症反应并考虑广谱抗微生物覆盖。

局限性

  • 单例病例报告,结论外推受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 57-year-old man who had been intubated and placed on venovenous extracorporeal membrane oxygenation for hypoxemic respiratory failure due to COVID-19 pneumonia was transferred to our facility. He underwent anticoagulation with IV heparin titrated to an anti-Factor Xa goal of 0.1 to 0.3 international unit/mL. Over extracorporeal membrane oxygenation days 13 to 17, his WBC count rose from 17,500 to 47,000 cells/μL. He simultaneously experienced the development of fluid-refractory shock that required multiple vasopressors and received stress-dose hydrocortisone when his WBC was 30,000 cells/μL. He remained afebrile and was started on broad-spectrum antimicrobials that included antifungal and anthelminthic therapy.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Krieger JA, Wixon-Genack JR, Mandell SP, et al. A 57-Year-Old Man With COVID-19 Pneumonia Who Required Venovenous Extracorporeal Life Support With a Rapidly Escalating WBC Count. Chest. 2021. PMID: 34366043. doi:10.1016/j.chest.2021.04.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。